Interestingly, a study showed that RAC1P29S, a common mutation in human cutaneous melanoma, drives BRAFi resistance through an SRF/MRTF program, which suppresses melanocytic differentiation, induces a mesenchymal-like phenotype and increases survival and resistance to BRAF inhibitor [70]. Here, BRAF is linked to cutaneous melanoma.